Skip to content

Advertisement

Volume 18 Supplement 1

19th Annual SCMR Scientific Sessions

  • Oral presentation
  • Open Access

Occult senile cardiac amyloid in severe calcific aortic stenosis is not rare and has a poor prognosis: a 146 patient CMR biopsy study

  • 1, 2,
  • 3, 2,
  • 3,
  • 3,
  • 1, 2,
  • 1, 2,
  • 1, 3,
  • 3,
  • 3,
  • 3,
  • 3,
  • 2,
  • 4,
  • 3 and
  • 1, 2
Journal of Cardiovascular Magnetic Resonance201618 (Suppl 1) :O40

https://doi.org/10.1186/1532-429X-18-S1-O40

  • Published:

Keywords

  • Prognostic Significance
  • Amyloidosis
  • Aortic Valve Replacement
  • Amyloid Deposition
  • Cardiac Amyloidosis

Background

Severe degenerative calcific aortic stenosis (cAS) affects 3% of the over 75 year-olds and leads to heart failure and death unless the valve is replaced. Coexisting cardiac amyloid - typically wild-type Transthyretin (wtATTR) has been reported but has not been systematically studied: its prevalence and prognostic significance are unknown. Multiparametric CMR (function, LGE, T1 and ECV mapping) has high sensitivity and specificity for cardiac amyloidosis. We sought, in cAS, to define the prevalence of occult cardiac amyloid by biopsy, subtype it, explore its CMR presentation and understand its prognostic significance.

Methods

As part of the RELIEF-AS study (NCT 02174471), 146 patients with severe AS awaiting aortic valve replacement (AVR) underwent CMR (LGE, T1 mapping) and intra-operative myocardial biopsies. 108 patients had calcific AS (cAS) [75 ± 6 years; 58% male]; the remainder had bicuspid (36), rheumatic (1) or unicuspid AS (1). Biopsies were screened for cardiac amyloid by congo red staining; if positive, tissue was fully sub-typed (immunohistochemistry, mass spectrometry as needed), and patients underwent full clinical amyloid assessment including genotyping and DPD (bone tracer) scintigraphy.

Results

Myocardial biopsy identified amyloid depositions in 6 out of 108 cAS patients (all age >65 years); none in the other cohorts. All were TTR. All were by genotyping wild-type. Two had definite cardiac amyloidosis by CMR and DPD, but were not recognized by routine pre-operative work-up (Figure 1). Four other patients had findings by multiparametric CMR that could be explained solely by severe AS (Table 1). At median follow-up of 1.9 years (0.4-4.2 years), 50% of the affected patients had died compared to 7.8% in the remaining cAS cohort. This was highly significant and, of all parameters assessed, the presence of TTR amyloid had the highest hazard ratio for death (HR 9.4 [2.4-35.6], p = 0.001, univariable Cox regression analysis).
Table 1

Pre-operative characteristics of patients with TTR on cardiac biopsy

 

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Age/Gender

73 female

69 male

80 female

85 male

84 male

71 male

Biopsy/Genotype

TTR/wild-type

TTR/wild-type

TTR/wild-type

TTR/wild-type

TTR/wild-type

TTR/wild-type

CMR LGE pattern*

Amyloidosis

Amyloidosis

AS

AS

AS

AS

ECV

60%

52%

31%

25%

32%

32%

LV mass index (g/m 2 )

137

150

117

101

93

132

DPD Scintigraphy

Grade 2

Grade 2

NA

Grade 1

NA

Grade 1

Peak AV Gradient (mmHg)

74

45

70

110

61

116

AVAi (cm 2 /m 2 )

0.36

0.52

0.6

0.34

0.35

0.24

Follow-up Status

Alive

Dead

Dead

Alive

Dead

Alive

*LGE pattern consistent with diagnosis of cardiac amyloidosis / aortic stenosis (AS)

Figure 1
Figure 1

Occult Transthyretin Amyloid Deposition in Aortic Stenosis; detected by CMR late gadolinium enhancement (LGE), histological congo red staining and DPD scintigraphy; Transthyretin deposits are associated with poor outcome in aortic stenosis (Kaplan-Meier-Plot).

Conclusions

Occult cardiac amyloid (wild-type TTR) has a prevalence of 6% in cAS undergoing surgical AVR (mean age 75). It has a poor outcome even when at low levels of infiltration. Multiparametric CMR becomes diagnostic in 1/3, but early disease looks like the changes of AS - here, DPD scanning adds value.

Authors’ Affiliations

(1)
Cardiac Imaging, Barts Heart Centre, London, UK
(2)
Institute of Cardiovascular Sciences, University College London, London, UK
(3)
National Amyloidosis Centre, Royal Free Campus, University College London, London, UK
(4)
Department of Histopathology, Great Ormond Street Hospital for Children, London, UK

Copyright

© Treibel et al. 2016

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement